Exploration of Clinical Characteristics and Drug Treatment of Inflammatory Bowel Disease Complicated with Autoimmune Diseases

Objective: To analyze the clinical characteristics and drug treatment outcomes of inflammatory bowel disease (IBD) complicated with autoimmune diseases. Methods: A total of 200 patients with IBD and autoimmune diseases were selected as the observation group from January 2022 to June 2023. In addition, 200 patients with simple IBD during the same period were selected as the control group. The general and clinical data of the two groups of patients were collected and analyzed to compare their clinical characteristics and drug treatment outcomes. Results: ① There were no significant differences in gender, age, lesion location, and clinical type between the two groups (P > 0.05). However, the two groups differed significantly in terms of disease duration, severity of the condition, and extraintestinal symptoms (P < 0.05). ② There was no significant difference in the use of microbial preparations between the two groups (P > 0.05). The observation group had a higher usage rate of steroids compared to the control group, while the usage rate of aminosalicylate suppositories was lower in the observation group than in the control group (P < 0.05). ③ There was no significant difference in treatment efficacy between the two groups (P > 0.05). Conclusion: Patients with IBD complicated by autoimmune diseases have longer disease duration, more severe conditions, and more extraintestinal symptoms compared to those with simple IBD. The usage rate of steroids is higher, while the usage rate of aminosalicylate suppositories is lower in the treatment plan for the former group. Nevertheless, the overall effectiveness is comparable to that of patients with simple IBD, and the overall prognosis is relatively favorable.